Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Jobs
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Jobs
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Verrica Pharmaceuticals Inc. - Common Stock
(NQ:
VRCA
)
6.060
+0.160 (+2.71%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 22, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
71,897
Open
5.920
Bid (Size)
6.020 (100)
Ask (Size)
6.220 (200)
Prev. Close
5.900
Today's Range
5.480 - 6.250
52wk Range
3.280 - 9.821
Shares Outstanding
41,957,197
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Verrica (VRCA) Q1 2026 Earnings Transcript
↗
May 13, 2026
Verrica (VRCA) Q1 2026 Earnings Transcript
Via
The Motley Fool
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
May 13, 2026
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Performance
YTD
-27.0%
-27.0%
1 Month
-13.2%
-13.2%
3 Month
+8.0%
+8.0%
6 Month
+28.4%
+28.4%
1 Year
+5.8%
+5.8%
More News
Read More
Verrica Pharmaceuticals Q1 Earnings Call Highlights
↗
May 12, 2026
Via
MarketBeat
Topics
Earnings
Verrica Pharmaceuticals (NASDAQ:VRCA) Q1 Results Beat Revenue Estimates as Pipeline Progress and Record Demand Drive Positive Momentum
↗
May 12, 2026
Via
Chartmill
Verrica Pharmaceuticals Inc (NASDAQ:VRCA) Reports Q4 Earnings Beat and Accelerating Revenue Growth
↗
March 11, 2026
Via
Chartmill
Topics
Earnings
Verrica Pharmaceuticals Reports First Quarter 2026 Financial Results
May 12, 2026
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Verrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investigative Dermatology (SID) Annual Meeting
May 05, 2026
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Verrica Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 12, 2026
May 05, 2026
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Verrica Pharmaceuticals Announces Acceptance of Late-Breaking Abstract Highlighting Potential Abscopal Effect of VP-315 for the Treatment of Basal Cell Carcinoma at the Upcoming 2026 Society for Investigative Dermatology Annual Meeting
April 09, 2026
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Verrica Pharmaceuticals to Participate in the 25th Annual Needham Virtual Healthcare Conference
April 06, 2026
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
VRCA Investors Have the Opportunity to Join Investigation of Verrica Pharmaceuticals Inc. with the Schall Law Firm
March 20, 2026
From
The Schall Law Firm
Via
Business Wire
VRCA Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Verrica Pharmaceuticals Inc. – VRCA
March 20, 2026
From
The Rosen Law Firm, P.A.
Via
Business Wire
Verrica Pharmaceuticals Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Verrica Pharmaceuticals Inc. – VRCA
March 19, 2026
From
The Rosen Law Firm, P.A.
Via
Business Wire
Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
March 11, 2026
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 11, 2026
March 05, 2026
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Verrica Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference
February 23, 2026
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Verrica Pharmaceuticals Appoints Chris Chapman as Chief Commercial Officer
February 12, 2026
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Verrica Pharmaceuticals Announces Launch of YCANTH® for the Treatment of Molluscum Contagiosum in Japan by Partner Torii Pharmaceutical
February 09, 2026
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Verrica Pharmaceuticals Announces First Patient Dosed in Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts
January 07, 2026
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Which stocks are gapping on Monday?
↗
December 01, 2025
Via
Chartmill
Top stock movements in today's session.
↗
November 28, 2025
Via
Chartmill
Which stocks are moving on Friday?
↗
November 28, 2025
Via
Chartmill
Verrica Pharmaceuticals Announces Private Placement Financing of $50 Million to Retire Debt and Extend Cash Runway
November 24, 2025
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Verrica Pharmaceuticals Reports Third Quarter 2025 Financial Results
November 14, 2025
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Verrica Pharmaceuticals Presents New Data on VP-315 from its Phase 2 Clinical Trial in Basal Cell Carcinoma at the 40th Society for Immunotherapy of Cancer Annual Meeting
November 10, 2025
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Frequently Asked Questions
Is Verrica Pharmaceuticals Inc. - Common Stock publicly traded?
Yes, Verrica Pharmaceuticals Inc. - Common Stock is publicly traded.
What exchange does Verrica Pharmaceuticals Inc. - Common Stock trade on?
Verrica Pharmaceuticals Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Verrica Pharmaceuticals Inc. - Common Stock?
The ticker symbol for Verrica Pharmaceuticals Inc. - Common Stock is VRCA on the Nasdaq Stock Market
What is the current price of Verrica Pharmaceuticals Inc. - Common Stock?
The current price of Verrica Pharmaceuticals Inc. - Common Stock is 6.060
When was Verrica Pharmaceuticals Inc. - Common Stock last traded?
The last trade of Verrica Pharmaceuticals Inc. - Common Stock was at 05/22/26 04:00 PM ET
What is the market capitalization of Verrica Pharmaceuticals Inc. - Common Stock?
The market capitalization of Verrica Pharmaceuticals Inc. - Common Stock is 254.26M
How many shares of Verrica Pharmaceuticals Inc. - Common Stock are outstanding?
Verrica Pharmaceuticals Inc. - Common Stock has 254M shares outstanding.
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today